Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated Locally Advanced or Metastatic NSCLC”

128 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 128 results

Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Large-scale testing (Phase 3)Not Yet RecruitingNCT07416994
What this trial is testing

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Testing effectiveness (Phase 2)Ended earlyNCT04044170
What this trial is testing

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Hanmi Pharmaceutical Company Limited 5
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Early research (Phase 1)Looking for participantsNCT07130916
What this trial is testing

Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Large-scale testing (Phase 3)Active Not RecruitingNCT05261399
What this trial is testing

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Who this might be right for
CarcinomaNon-Small-Cell Lung
AstraZeneca 345
Testing effectiveness (Phase 2)Looking for participantsNCT06043817
What this trial is testing

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Who this might be right for
Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament 345
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05007938
What this trial is testing

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Large-scale testing (Phase 3)Study completedNCT02044380
What this trial is testing

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 14
Large-scale testing (Phase 3)Active Not RecruitingNCT04487080
What this trial is testing

Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 1,074
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902
What this trial is testing

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 104
Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Large-scale testing (Phase 3)Study completedNCT01953913
What this trial is testing

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 542
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Load More Results
480